1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Antibody Drugs: Technologies and Global Markets

Antibody Drugs: Technologies and Global Markets

  • January 2015
  • -
  • BCC Research
  • -
  • 141 pages

REPORT HIGHLIGHTS

The global market for antibody drugs was worth nearly $63.4 billion in 2013. This market is expected to grow at a compound annual growth rate (CAGR) of 12.2% between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019.

This report provides:

An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
Analysis and assessment of the therapeutic applications of mAbs in human medicine.
A look at the antibody industry as a whole as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

SCOPE OF THE STUDY

The scope of this report embraces the key market analysis, market drivers, market constraints, and also competitive developments and trends in this market. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares.
The study involves the antibody drugs used in the pharmaceutical and the biopharmaceutical markets. This report analyzes and assesses therapeutic applications of mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agent such as with antibody-drug conjugates (ADCs).
Excluded from this report is information regarding polyclonal antibodies, as well as screening equipment and diagnostic uses (such as for imaging purposes) of mAbs. Also excluded is discussion relating to the research applications of mAbs and therapeutic antibodies for veterinary use.

Complete geographical analysis of market is also studied in report. The emerging market for mAbs includes countries such as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth. Profiles of key market players are also covered for this report. The U.S. and Europe markets are also covered.
The technological issues include all the latest trends, for example, the human antimouse antibody (HAMA) problem because of murine antibodies and its resolution by using chimeric, human and humanized antibodies instead of murine antibodies for therapy, pipeline products and developments. Also included in the report are comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development (R&D) of antibody drugs.

Table Of Contents

Antibody Drugs: Technologies and Global Markets

Chapter- 1: INTRODUCTION - Complimentary 4

STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter- 2: SUMMARY 2

Table Summary : GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019
Figure Summary : GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, 2012-2019

Chapter- 3: OVERVIEW 15

DEFINITIONS
MONOCLONAL ANTIBODIES

Chapter- 4: REGULATORY ASPECTS 8

RECALLS
NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS
SAFETY ALERTS
Table 14 : NEW APPROVALS OF MONOCLONAL ANTIBODIES FROM JANUARY 2009 TO MAY 2014

Chapter- 5: NEW DEVELOPMENTS 15

PHASE I CLINICAL TRIALS
PHASE II CLINICAL TRIALS
PHASE III CLINICAL TRIALS
PHASE IV CLINICAL TRIALS
MERGERS AND ACQUISITIONS

Chapter- 6: MARKET ANALYSIS OF ANTIBODY DRUGS 30 $2122

MARKET BY TYPE
MARKET BY REGION
MARKET BY MANUFACTURING PROCESS

Chapter- 7: MARKET APPLICATIONS OF ANTIBODY DRUGS 28

MARKET BY DISEASES
GLOBAL ANTIBODY DRUG MARKET BY DISEASES

Chapter- 8: INDUSTRY STRUCTURE 8

MURINE MONOCLONAL ANTIBODIES
CHIMERIC MONOCLONAL ANTIBODIES
HUMANIZED MONOCLONAL ANTIBODIES
HUMAN MONOCLONAL ANTIBODIES

Chapter- 9: PATENT ANALYSIS 9

PATENTS BY YEAR
PATENTS BY TYPE/CATEGORY
PATENTS BY COMPANY
PATENTS BY COUNTRY
PATENTS BY ASSIGNEE

Chapter- 10: CURRENT SITUATION 9

TECHNICAL ISSUES
NEW TECHNOLOGIES IN ANTIBODY DEVELOPMENT
OTHER ADVANCES IN ANTIBODIES DEPENDING ON THE TREATMENT
FACTORS AFFECTING THE MONOCLONAL ANTIBODY DRUG MARKET

Chapter- 11: COMPANY PROFILES 11

ABBOTT LABORATORIES
ALEXION PHARMACEUTICALS
AMGEN
BIOGEN IDEC
BRISTOL-MYERS SQUIBB
ELI LILLY AND CO.
GLAXOSMITHKLINE
HOFFMAN-LA ROCHE
JOHNSON and JOHNSON
MERCK and CO.
MERCK KGAA
NOVARTIS
SEATTLE GENETICS INC.
SPECTRUM PHARMACEUTICALS
TAKEDA PHARMACEUTICAL U.S.A. INC.
UCB COMPANY

Chapter- 12: APPENDIX ABBREVIATIONS 2

List of Tables

Summary Table : GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019
Table 1 : EVOLUTION OF MONOCLONAL ANTIBODIES
Table 2 : ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
Table 3 : DIFFERENCES BETWEEN MONOCLONAL ANTIBODY DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
Table 4 : MURINE MONOCLONAL ANTIBODIES
Table 5 : CHIMERIC MONOCLONAL ANTIBODIES
Table 6 : HUMANIZED MONOCLONAL ANTIBODIES
Table 7 : HUMAN MONOCLONAL ANTIBODIES
Table 8 : DIFFERENCES BETWEEN HYBRIDOMA TECHNOLOGY AND RECOMBINANT TECHNOLOGY
Table 9 : COMPARISON OF VARIOUS EXPRESSION SYSTEMS FOR RECOMBINANT PHARMACEUTICAL PROTEINS
Table 10 : MURINE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
Table 11 : CHIMERIC MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
Table 12 : HUMAN MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
Table 13 : HUMANIZED MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
Table 14 : NEW APPROVALS OF MONOCLONAL ANTIBODIES FROM JANUARY 2009 TO MAY 2014
Table 15 : RECALLS FROM JANUARY 2009 TO JUNE 2014
Table 16 : NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS FROM JANUARY 2009 TO JANUARY 2014
Table 17 : SAFETY ALERTS FROM 2010 TO MAY 2014
Table 18 : MONOCLONAL ANTIBODIES IN PHASE I CLINICAL TRIALS
Table 19 : MONOCLONAL ANTIBODIES IN PHASE II CLINICAL TRIALS
Table 20 : MONOCLONAL ANTIBODIES IN PHASE III CLINICAL TRIALS
Table 21 : MONOCLONAL ANTIBODIES IN PHASE IV CLINICAL TRIALS
Table 22 : MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES FROM 2009 TO JUNE 2014
Table 23 : GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, THROUGH 2019
Table 24 : MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013
Table 25 : GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, THROUGH 2019
Table 26 : MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013
Table 27 : GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019
Table 28 : GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019
Table 29 : GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019
Table 30 : GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019
Table 31 : GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, THROUGH 2019
Table 32 : MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013
Table 33 : GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, THROUGH 2019
Table 34 : GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019
Table 35 : GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019
Table 36 : GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019
Table 37 : GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, THROUGH 2019
Table 38 : MARKET SHARES FOR ANTIBODY DRUGS BY DISEASES, 2013
Table 39 : VARIOUS TYPES OF AUTOIMMUNE DISEASES
Table 40 : GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, THROUGH 2019
Table 41 : GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, THROUGH 2019
Table 42 : VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
Table 43 : GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, THROUGH 2019
Table 44 : GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, THROUGH 2019
Table 45 : TYPES OF LYMPHOMAS
Table 46 : TYPES OF LEUKEMIA
Table 47 : GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, THROUGH 2019
Table 48 : GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, THROUGH 2019
Table 49 : GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY TYPE, THROUGH 2019
Table 50 : GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, THROUGH 2019
Table 51 : LEADING MANUFACTURERS/SUPPLIERS OF MURINE MONOCLONAL ANTIBODIES, 2013
Table 52 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013
Table 53 : LEADING MANUFACTURERS/SUPPLIERS OF CHIMERIC MONOCLONAL ANTIBODIES, 2013
Table 54 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013
Table 55 : LEADING MANUFACTURERS/SUPPLIERS OF HUMANIZED MONOCLONAL ANTIBODIES, 2013
Table 56 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013
Table 57 : LEADING MANUFACTURERS/SUPPLIERS OF HUMAN MONOCLONAL ANTIBODIES, 2013
Table 58 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013
Table 59 : NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014
Table 60 : NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014
Table 61 : NUMBER OF PATENTS BY COMPANY, 2009-JUNE 2014
Table 62 : NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014
Table 63 : PATENT SHARES BY COUNTRY, 2009-JUNE 2014
Table 64 : NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014
Table 65 : NANOBODIES IN DEVELOPMENT

List of Figures

Summary Figure : GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, 2012-2019
Figure 1 : GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, 2012-2019
Figure 2 : MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013
Figure 3 : GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, 2012-2019
Figure 4 : MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013
Figure 5 : GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, 2012-2019
Figure 6 : GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, 2012-2019
Figure 7 : GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, 2012-2019
Figure 8 : GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, 2012-2019
Figure 9 : GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, 2012-2019
Figure 10 : MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013
Figure 11 : GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2012-2019
Figure 12 : GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019
Figure 13 : GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019
Figure 14 : GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019
Figure 15 : GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, 2012-2019
Figure 16 : MARKET SHARE FOR ANTIBODY DRUGS BY DISEASES, 2013
Figure 17 : GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, 2012-2019
Figure 18 : GLOBAL MARKET FOR ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, 2012-2019
Figure 19 : GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, 2012-2019
Figure 20 : GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, 2012-2019
Figure 21 : GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, 2012-2019
Figure 22 : GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, 2012-2019
Figure 23 : GLOBAL REVENUE OF ANTIBODY DRUGS BY APPLICATION IN OTHER DISEASES BY TYPE, 2012-2019
Figure 24 : GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, 2012-2019
Figure 25 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013
Figure 26 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013
Figure 27 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013
Figure 28 : MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013
Figure 29 : NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014
Figure 30 : NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014
Figure 31 : NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014 (%)
Figure 32 : NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic ...

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Monoclonal Antibody ...

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.